{"nctId":"NCT01493947","briefTitle":"CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study","startDateStruct":{"date":"2012-04"},"conditions":["Papulopustular Rosacea"],"count":962,"armGroups":[{"label":"Ivermectin 1% cream","type":"EXPERIMENTAL","interventionNames":["Drug: Ivermectin 1% cream"]},{"label":"Metronidazole 0.75% cream","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metronidazole 0.75% cream"]}],"interventions":[{"name":"Ivermectin 1% cream","otherNames":["Soolantra"]},{"name":"Metronidazole 0.75% cream","otherNames":["Metronidazole"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with papulopustular rosacea scored 3 (moderate) or 4 (severe) according to the Investigator Global Assessment (IGA),\n* Subjects with at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.\n\nExclusion Criteria:\n\n* Subjects with particular forms of rosacea (rosacea conglobate, rosacea fulminant, isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial keratosis pilar, or seborrheic dermatitis and acne,\n* Subjects with rosacea with more than two nodules on the face.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Inflammatory Lesions From Baseline to Week 16","description":"Efficacy of Ivermectin versus Metronidazole as determined by the percent change in inflammatory lesions after a 16-week treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-83","spread":"26"},{"groupId":"OG001","value":"-73.7","spread":"39.7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Relapse","description":"Relapse define as time elapsed between Week 16 and first reoccurrence of Investigator Global assessement (IGA) at '2 (mild)' , '3 (moderate)' or '4 (severe)'.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":478},"commonTop":["Nasopharingitis","Influenza","Headache","Back Pain","Hypertension"]}}}